Kymera Therapeutics, Inc. (KYMR) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Kymera Therapeutics’s revenue went from $3M in fiscal 2019 to $39M in fiscal 2025, growth of about 54.0% a year.
Net income in fiscal 2025 was -$311M, a net margin of -794.0%; the best year in this period was 2019 with -$41M.
Over the twelve months to September 30, 2026, revenue was $102M and net income -$349M.
Free cash flow was -$234M in fiscal 2025 and positive in 2 of the 7 years shown.
The diluted share count rose 4874% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $102M | $39M | $47M | $79M | $47M | $73M | $34M | $3M |
| Gross profit | $0 | $0 | $0 | $0 | $0 | — | — | — |
| Operating income | -$405M | -$349M | -$262M | -$166M | -$161M | -$101M | -$46M | -$42M |
| Net income | -$349M | -$311M | -$224M | -$147M | -$155M | -$100M | -$46M | -$41M |
| EPS (diluted) | $-3.63 | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | $-24.28 |
| R&D | $430M | $317M | $240M | $189M | $164M | $137M | $62M | $37M |
| Revenue growth | — | −16.7% | −40.1% | +67.8% | −35.7% | +114.0% | +1060.0% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$288M | -$233M | -$195M | -$103M | -$153M | -$129M | $88M | $18M |
| Capital spending | -$1M | -$1M | -$13M | -$34M | -$3M | -$2M | -$9M | -$532000 |
| Free cash flow | -$289M | -$234M | -$207M | -$137M | -$156M | -$131M | $79M | $17M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — |
| Stock-based pay | $68M | $60M | $55M | $43M | $35M | $25M | $5M | $1M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $848M | $489M | $375M | $407M | $442M | $296M | $92M |
| Debt | — | $79M | $84M | $82M | $15M | $16M | $17M | $19M |
| Equity | — | $1.6B | $836M | $395M | $490M | $460M | $284M | -$74M |
| Total assets | — | $1.7B | $978M | $576M | $603M | $606M | $487M | $117M |
| Shares (diluted) | 100M | 84M | 75M | 58M | 54M | 48M | 17M | 2M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Operating margin | -396.0% | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% | -136.1% | -1438.5% |
| Net margin | -341.8% | -794.0% | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% | -1405.8% |
| FCF margin | -282.6% | -597.6% | -440.5% | -174.7% | -333.0% | -179.2% | 232.2% | 592.1% |
| ROIC | — | -21.1% | -22.5% | -27.4% | -25.2% | -16.7% | -12.2% | — |
| ROE | — | -19.7% | -26.8% | -37.2% | -31.6% | -21.8% | -16.1% | 55.4% |
Frequently asked questions
What is Kymera Therapeutics’s annual revenue?
$39M in fiscal 2025 and $102M over the twelve months to September 30, 2026.
How much profit does Kymera Therapeutics make?
Net income was -$311M in fiscal 2025 (net margin -794.0%).
Is Kymera Therapeutics’s revenue growing?
No: revenue fell 16.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.